Ashkan Rasouli-Saravani

Ashkan Rasouli-Saravani

Auto-generated profile, based on publicly available information

Ashkan Rasouli-Saravani

Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 August 2022 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
ENEbrahim Nadi
Ebrahim Nadi
GGGhazal Geramirad
Ghazal Geramirad
ZKZohreh Kahramfar
Zohreh Kahramfar
ARAshkan Rasouli-Saravani
Ashkan Rasouli-Saravani
GSGhasem Solgi
Ghasem Solgi
Altered expression and dysregulation of microRNAs (miRNAs) have been reported in different samples of chronic obstructive pulmonary disease (COPD) patients. The present study attempted to evaluate the peripheral expressions of miR-146a and miR-218 in COPD patients and sex-matched healthy controls with/without cigarette smoke exposure (CSE). In this case-control study, blood samples were collected from 60 COPD patients (30 with CSE and 30 non-CSE in each group) and 60 healthy controls. Peripheral expressions of miRNA-146a and miR-218a were measured using qRT-PCR and results were compared between cases and controls as well as within the subgroups of patients. We found significantly decreased expressions for both miRNAs in the patients compared to healthy controls. Remarkable underexpression of miRNA-146a and miRNA-218 were found in the CSE and non-CSE patients compared to non-CSE healthy controls and even in the CSE versus non-CSE controls. Both groups of patients showed underexpression of two miRNAs in comparison with CSE healthy controls and interestingly, similar decrements were observed in the CSE versus non-CSE patients. Also, ROC curve analysis revealed the significantly diagnostic powers for both miRNAs in discrimination of patients from healthy individuals and CSE-COPD from non-CSE COPD patients. The underexpression of miR-146a and miR-218 in COPD patients and relation to CSE can be indicative of CSE-induced changes in miRNA expression profile and potential for these biomarkers in COPD risk assessment, particularly in those patients with CSE.

14 February 2021 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
ARAshkan Rasouli-Saravani
Ashkan Rasouli-Saravani
ATAhmad Tahamoli-Roudsari
Ahmad Tahamoli-Roudsari
MBMahdi Behzad
Mahdi Behzad
MHMehrdad Hajilooi
Mehrdad Hajilooi
GSGhasem Solgi
Ghasem Solgi
Given the potential link between genetic risk factors and clinical features of systemic lupus erythematosus (SLE), this study aimed to explore the relationship between human leukocyte antigen (HLA)-DRB1/DQB1 alleles and haplotypes and clinical sub-phenotypes of the disease in a group of Iranian SLE patients. HLA-DRB1 and HLA-DQB1 alleles were determined by PCR-SSP in 127 SLE patients and 153 ethnically-matched healthy controls. The relationships between various clinical manifestations and HLA alleles/haplotypes were analyzed in the patients. We observed the positive associations of DRB1*07 and DRB1*07-DQB1*02 haplotypes with articular and pulmonary involvement (p=0.006 and p<0.001 respectively), DRB1*03 and DQB1*02 alleles, and DRB1*03-DQB1*02 haplotypes with cutaneous (p=0.03, p=0.004 and p=0.02 respectively) and renal involvement, and DRB1*13 as well as DRB1*13-DQB1*06 haplotypes with renal involvement. Conversely, negative associations of DRB1*13 with cutaneous and gastrointestinal disorders (p=0.004 and p=0.02 respectively) and DRB1*01 with renal involvement (p=0.03) were found in our patients. Patients carrying susceptible HLA-DRB1 alleles had a higher risk for expression of cutaneous involvement (p=0.03), anti-coagulant antibody development (p=0.01), and a lower risk for pulmonary disorders compared to patients' negatives for susceptible alleles (p=0.04). Our findings on associations between HLA risk allele (DRB1*03) as well as non-risk alleles with particular clinical manifestations and between the potentially protective allele (DRB1*01) and protection against renal involvement indicate the important role of HLA class II genes in predisposing of specific serological and clinical features of SLE disease which could be implicative for therapeutic applications and better management of SLE patients.

29 January 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ARAshkan Rasouli-Saravani
Ashkan Rasouli-Saravani
HGHossein Ghanbarian
Hossein Ghanbarian
FRFahimeh Ramezani-Tehrani
Fahimeh Ramezani-Tehrani
NMNariman Mosaffa
Nariman Mosaffa
SGSahar Ghaffari-Khaligh
Sahar Ghaffari-Khaligh
SHSeyed Mahmoud Hashemi
Seyed Mahmoud Hashemi

4 April 2025
Verified
Book Chapter
Closed access
PDF file
FGFarid Ghorbaninezhad
Farid Ghorbaninezhad
AVAhmad Ghorbani Vanan
Ahmad Ghorbani Vanan
ARAshkan Rasouli-Saravani
Ashkan Rasouli-Saravani
KRKimiya Rashidan
Kimiya Rashidan
KJKasra Jahankhani
Kasra Jahankhani
ESElham Safarzadeh
Elham Safarzadeh